These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7883025)

  • 1. Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist.
    Parker SG; Raval P; Yeulet S; Eden RJ
    Eur J Pharmacol; 1994 Nov; 265(1-2):17-26. PubMed ID: 7883025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors.
    Lahlou S; Duarte GP
    Fundam Clin Pharmacol; 1998; 12(6):599-606. PubMed ID: 9917201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats.
    Lahlou S
    Pharmacol Toxicol; 2001 May; 88(5):238-43. PubMed ID: 11393583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.
    de Mey C; Enterling D; Meineke I; Yeulet S
    Br J Clin Pharmacol; 1991 Oct; 32(4):483-8. PubMed ID: 1683559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
    Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
    Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
    Coldwell MC; Boyfield I; Brown T; Hagan JJ; Middlemiss DN
    Br J Pharmacol; 1999 Aug; 127(7):1696-702. PubMed ID: 10455328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction.
    Garrett BE; Holtzman SG
    Eur J Pharmacol; 1994 Sep; 262(1-2):65-75. PubMed ID: 7813580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats.
    McCoy CE; Douglas FL; Goldberg LI
    Hypertension; 1986 Apr; 8(4):298-302. PubMed ID: 2870024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats.
    Lahlou S
    Fundam Clin Pharmacol; 1999; 13(6):624-34. PubMed ID: 10626749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
    Fukuzaki K; Kamenosono T; Nagata R
    Pharmacol Biochem Behav; 2000 Mar; 65(3):503-8. PubMed ID: 10683491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of spinal dopamine receptors in mediation of the hypotensive and bradycardic effects of systemic quinpirole in anaesthetised rats.
    Lahlou S
    Eur J Pharmacol; 1998 Jul; 353(2-3):227-37. PubMed ID: 9726652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure effects of intravenous apomorphine in conscious deoxycorticosterone-acetate salt-hypertensive rats.
    Toscano CF; Lahlou S
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):772-81. PubMed ID: 14639100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
    Dhir A; Kulkarni SK
    Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
    Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.
    Rogers DC; Costall B; Domeney AM; Gerrard PA; Greener M; Kelly ME; Hagan JJ; Hunter AJ
    Psychopharmacology (Berl); 2000 Jul; 151(1):91-7. PubMed ID: 10958122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum.
    Kohno Y; Fukuzaki K; Kitahara K; Koja T
    Eur J Pharmacol; 1997 Jan; 319(2-3):197-205. PubMed ID: 9042591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-512, a novel dopamine D
    Lindenbach D; Das B; Conti MM; Meadows SM; Dutta AK; Bishop C
    Br J Pharmacol; 2017 Sep; 174(18):3058-3071. PubMed ID: 28667675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.